Drugs / 18F-αvβ6-BP
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT04376593 | May 2020 → Feb 2026 | COVID-19 | University of California, Davis | Completed | No outcome recorded |
| Phase 0 | NCT03164486 | Nov 2016 → Dec 2026 expected | breast carcinoma, lung carcinoma, metastatic malignant neoplasm in the colon, rectal carcinoma | Julie L. Sutcliffe, Ph.D | Active not recruiting | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT05452005 | Sep 2022 → Dec 2026 expected | metastatic malignant neoplasm in the brain, non-small cell lung carcinoma | University of California, Davis | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 18F-αvβ6-BP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04376593 ↗ |
| Modality | Diagnostic / imaging agent | “Radiotracers, such as 18F-alphavbeta6-binding-peptide, may improve the ability to locate cancer in the body.” NCT03164486 ↗ |
| Route | Intravenous | “rapid intravenous bolus” NCT03164486 ↗ |